With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

Key Takeaways Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its ...

Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F. The Food and Drug Administration ...

Though Blenrep is also approved in Europe, the drug’s sales have been significantly impacted owing to its withdrawal from the U.S. markets. Blenrep sales plunged 67% at constant exchange rate in ...

GSK ’s GSK 0.04% blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to market next year. The data showed ...

Treatment of Blenrep (belantamab mafodotin) in combination with Velcade (bortezomib) plus dexamethasone significantly improved progression-free survival compared with standard treatment for patients ...

GSK plc is looking at a comeback for Blenrep (belantamab mafodotin) as an interim efficacy analysis brought the company good news. Almost exactly a year ago, phase III confirmatory study data for the ...

An interim analysis of the DREAMM-8 trial showed belantamab mafodotin (Blenrep) improved progression-free survival when combined with pomalidomide (Pomalyst) and dexamethasone as second-line ...

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome ...

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA, a cell-surface protein that plays an important role in the survival of plasma cells and is expressed on multiple ...